<SEC-DOCUMENT>0001193125-24-135386.txt : 20240509
<SEC-HEADER>0001193125-24-135386.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509171220
ACCESSION NUMBER:		0001193125-24-135386
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278989
		FILM NUMBER:		24931871

	BUSINESS ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804
		BUSINESS PHONE:		(518) 743-8892

	MAIL ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d820991d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:71%; font-size:10pt; font-family:Times New Roman"><B>Filed Pursuant to Rule 424(b)(3)<BR> Registration No. 333-278989 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g820991g27y90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>1,918,140 Shares of Common Stock Offered by the Selling Stockholders</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading &#147;Selling Stockholders&#148; in
this prospectus, or their assigns (the &#147;Selling Stockholders&#148;), of 1,918,140&nbsp;shares (the &#147;Shares&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;Common Stock&#148;), which consist of (i)
1,806,427&nbsp;shares of Common Stock, (ii) 77,641 shares of Common Stock (the &#147;PIPE Warrant Shares&#148; and together with the 1,806,427&nbsp;Shares, the &#147;PIPE Securities&#148;) issuable upon the exercise of pre-funded warrants (the
&#147;PIPE Warrants&#148;) held by certain Selling Stockholders, and (iii)&nbsp;34,072 shares of Common Stock that were issued upon the exercise of pre-funded warrants to purchase Common Stock (the &#147;Avenue Amendment Warrants&#148;) previously
issued by the Company pursuant to an amendment to the Loan and Security Agreement dated as of March&nbsp;31, 2023 (the &#147;Amended Avenue Agreement&#148;) with Avenue Venture Opportunities Fund, L.P. (&#147;Avenue&#148;), all of which were
exercised. We are registering the offer and sale of the PIPE Securities to satisfy the registration rights they were granted pursuant to a registration rights agreement entered into on March&nbsp;14, 2024 in connection with the securities purchase
agreement entered into on March&nbsp;14, 2024. We are registering the offer and sale of the shares of Common Stock outstanding upon exercise of the Avenue Amendment Warrants to satisfy the registration rights that were granted pursuant to the
Amended Avenue Agreement. While we will not receive any proceeds from the sale of the Shares by the Selling Stockholders, we will receive proceeds from the exercise of any PIPE Warrants for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registration of the Shares covered by this prospectus does not mean that the Selling Stockholders will offer or sell any such Shares. The Selling
Stockholders may sell Shares covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of sale that may be used by the Selling Stockholders, you should refer to the section of
this prospectus entitled &#147;Plan of Distribution.&#148; The Selling Stockholders may, individually but not severally, be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;), of the Shares that they are offering pursuant to this prospectus. The Selling Stockholders will bear all commissions and discounts, if any, attributable to their respective sales of Common Stock hereunder. We will bear all costs,
expenses and fees in connection with the registration of the Common Stock. We will not be paying any underwriting discounts or commissions in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add, update, or change information contained in this prospectus. You should carefully read this prospectus, any applicable
prospectus supplement, and the information incorporated by reference in this prospectus and any applicable prospectus supplement before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on The Nasdaq Capital Market under the symbol &#147;DCTH.&#148; On May 9, 2024, the closing price for our Common Stock, as reported
on The Nasdaq Capital Market, was $5.56 per share. Our common stock outstanding as of April 24, 2024 was 27,784,384. Our principal executive offices are located at 566 Queensbury Avenue, Queensbury, NY 12804. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in these securities involves certain risks. See &#147;<A HREF="#toc820991_4">Risk Factors</A>&#148; on page&nbsp;6&nbsp;of this prospectus and in
the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is&nbsp;May 9, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc820991_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> which we have filed with the Securities and Exchange
Commission, or the SEC, using a &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Stockholders may from time to time sell the Common Stock described in this prospectus in one or more offerings or otherwise as
described under &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus may be supplemented from time to time by one or more prospectus supplements. Such
prospectus supplements may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in
the prospectus supplement. You should carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#147;Where You Can Find More Information&#148; before deciding to
invest in any Common Stock being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Stockholders have authorized anyone to provide any information other than that
contained or incorporated by reference in this prospectus or in any applicable prospectus supplement or any applicable free writing prospectus that we have authorized. We take no responsibility for and can provide no assurance as to the reliability
of, any other information that others may give you. The Common Stock is not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this prospectus
is accurate as of any date other than the respective dates of such document. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to, &#147;Delcath,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;our,&#148; or
&#147;us&#148; mean Delcath Systems, Inc. and its wholly owned subsidiaries. The term &#147;Selling Stockholders&#148; refers, collectively, to the selling stockholders named under the heading &#147;Selling Stockholders&#148; in this prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus summary highlights certain information about us and selected information contained elsewhere in or incorporated by reference into this
prospectus. This prospectus summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of the Company, you should read and consider carefully
the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement or amendment, including the factors described under the heading &#147;Risk Factors<I>,</I>&#148; beginning on page 6 of
this prospectus, as well as the information incorporated herein by reference, before making an investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an interventional oncology company focused on the treatment of primary and cancers metastatic to the liver. Our lead product, the HEPZATO<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> KIT ( melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the US Food and Drug Administration (the &#147;FDA&#148;) on August&nbsp;14, 2023, with an
indication as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes,
subcutaneous tissues, or lung that is amenable to resection, or radiation. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT (&#147;HEPZATO&#148;), but without the melphalan
hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers in the liver. The first commercial use of
HEPZATO for the treatment of metastatic hepatic dominant uveal melanoma (&#147;mUM&#148;) took place in January 2024. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO is
considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA&#146;s Center for Drug Evaluation and Research. The FDA has granted us six orphan
drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the
treatment of patients with hepatocellular carcinoma). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have sufficient raw material and component constituent parts of HEPZATO KIT to meet the first
year of our anticipated demand and we intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;28, 2022, CHEMOSAT received Medical Device Regulation (MDR) certification under the European Medical Devices Regulation (EU) 2017/745, which
may be considered by jurisdictions when evaluating reimbursement. As of March&nbsp;1, 2022, we have assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with metastatic hepatic dominant Uveal Melanoma (the
&#147;FOCUS Trial&#148;), a global registration clinical trial that investigated objective response rate in patients with mUM. The current focus of the Company&#146;s clinical development program is to generate clinical data for CHEMOSAT and HEPZATO
in patients with mUM, either as monotherapy or in combination with immunotherapy. We expect that this will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and to support reimbursement in various jurisdictions,
including the United States. In addition to HEPZATO&#146;s use to treat mUM, we believe that CHEMOSAT and HEPZATO has the potential to treat cancers in the liver, such as metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic
breast cancer and intrahepatic cholangiocarcinoma, and we plan to begin one or more studies of HEPZATO KIT to treat such conditions in 2024. We believe that those and similar disease states are areas of unmet medical needs that represent significant
market opportunities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2024, we
entered into a securities purchase agreement (the &#147;Securities Purchase Agreement&#148;) with certain accredited investors (each an &#147;Investor&#148; and collectively, the &#147;Investors&#148;) pursuant to which we agreed to sell and issue
to the Investors in a private placement (the &#147;Private Placement&#148;) (i) an aggregate of 876,627 shares (the &#147;Shares&#148;) of Common Stock, par value $0.01 per share (the &#147;Common Stock&#148;), at a purchase price of $3.72&nbsp;per
share, and (ii) to certain investors, in lieu of shares of Common Stock, 1,008,102 pre-funded warrants (the &#147;Pre-Funded Warrants&#148;) at a price per Pre-Funded Warrant of $3.71 (the &#147;PIPE Warrant Shares&#148; and together with the
Shares, the &#147;PIPE Securities&#148;). The Pre-Funded Warrants will have an exercise price of $0.01&nbsp;per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. Since the closing of the Private
Placement, 930,461 of PIPE Warrants have been exercised via cashless exercise, such that we are registering 1,806,427 shares of Common Stock and 77,641 PIPE Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement closed on March&nbsp;19, 2024. We received gross proceeds from the Private Placement of approximately $7.0&nbsp;million, before
deducting offering expenses payable by us. We intend to use the net proceeds of the Private Placement for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the PIPE Warrants issued to the Investors, nor the PIPE Securities were initially registered under the&nbsp;Securities Act or any state securities
laws. We have relied on the exemption from the registration requirements of the Securities Act by virtue of Section&nbsp;4(a)(2) thereof and Rule&nbsp;506 of Regulation D thereunder. In connection with each Investor&#146;s execution of the Purchase
Agreement, such Investor represented to us that it is an &#147;accredited investor&#148; as defined in Regulation&nbsp;D of the Securities Act and that the PIPE Warrants purchased by it were acquired solely for its own account and for investment
purposes and not with a view to the future sale or distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2024, in connection with the Private Placement, we entered into a Registration Rights Agreement with Investors (the &#147;Registration Rights
Agreement&#148;), providing for the registration for resale of the PIPE Securities pursuant to a registration statement (the &#147;Registration Statement&#148;) to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on or
prior to May&nbsp;13, 2024. We have agreed to use our best efforts to cause the Registration Statement to be declared effective as soon as possible, but in no event later than 75 days of the closing of the Private Placement (or 120 days in the event
of a full review of the Registration Statement by the SEC), and to keep the Registration Statement continuously effective for a period that extends from the first date on which the SEC issues an order of effectiveness in relation to the Registration
Statement until such date that all registrable securities (as such term is defined in the Registration Rights Agreement) covered by the Registration Statement have been sold thereunder or pursuant to Rule 144 or may be sold without volume or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule
144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term Loan from Avenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2021,
we entered into a Loan and Security Agreement and Supplement to Loan and Security Agreement (together, the &#147;Loan Agreement&#148;) with Avenue for a term loan in an aggregate principal amount of up to $20.0&nbsp;million (the &#147;Loan&#148;).
The Loan bears interest at an annual rate equal to the greater of (a)&nbsp;the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The Loan is secured by a security interest in all of the Company&#146;s assets.
The Loan maturity date is August&nbsp;1, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial tranche of the Avenue Loan was $15.0&nbsp;million, including $4.0&nbsp;million that was funded
into a restricted account. Up to $3.0&nbsp;million of the principal amount of the Avenue Loan outstanding may be converted, at Avenue&#146;s option, into shares of Common Stock at a conversion price of $11.98 per share. On March&nbsp;15, 2023,
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company returned to Avenue $4.0&nbsp;million held in the restricted cash to pay down a portion of the outstanding loan balance, principal payments of $2.1&nbsp;million and an incremental
4.25% of the final payment of $0.2&nbsp;million. On March&nbsp;31, 2023, we entered into the Amended Avenue Agreement to defer the interest only period to September&nbsp;30, 2023, with an additional extension option upon FDA Approval for the HEPZATO
KIT and subsequent receipt of at least $10&nbsp;million from the sale and issuance of equity securities. On August&nbsp;14, 2023, the Company received FDA approval and has subsequently received over $10&nbsp;million from the exercise of Tranche A
Preferred Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the initial entry into the Avenue Loan Agreement, we issued warrants to Avenue (the &#147;Initial Avenue
Warrant&#148;) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Initial Avenue Warrant is exercisable until August&nbsp;31, 2026. The 127,755 shares were registered pursuant to a registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-260097).</FONT> Additionally, in connection with the Avenue Amendment, the Company issued to Avenue the Avenue Amendment Warrants to
purchase up to 34,072 shares of Common Stock. The Loan Agreement requires that the Company prepare and file with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;to</FONT> register all of the shares of Common
Stock issuable upon the exercise of the Loan Conversion and the Avenue Amendment Warrants. The shares of Common Stock registered hereunder pursuant to the Loan Agreement include only the 34,072 shares of Common Stock outstanding following the
exercise, in full, of the Avenue Amendment Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware in August 1988. Our corporate offices are located at 566 Queensbury Avenue, Queensbury, New York 12804. Our
telephone number is (212) <FONT STYLE="white-space:nowrap">489-2100</FONT> and our internet address is www.delcath.com. Information contained in, or accessible through, our website does not constitute any part of, and is not incorporated into, this
prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_3"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale from time to time by the Selling Stockholders identified in this prospectus of 1,918,140 Shares, which consist of
(i)&nbsp;1,806,427 shares of Common Stock held by the Selling Stockholders; (ii)&nbsp;77,641&nbsp;PIPE Warrant Shares (and together with the Shares, the &#147;Securities&#148;) issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> held by the Selling Stockholders; and (iii)&nbsp;34,072&nbsp;shares of Avenue Amendment Warrants held by the Selling Stockholders. While we will not receive any proceeds from the sale
of the Common Stock by the Selling Stockholders, we will receive proceeds from the exercise of any PIPE Warrants for cash. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Issuer </I></B></P></TD>
<TD>Delcath Systems, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock offered by the Selling Stockholders </I></B></P></TD>
<TD>(i) 1,840,499&nbsp;shares of Common Stock and (ii)&nbsp;77,641 PIPE Warrant Shares issuable upon the exercise of the PIPE Warrants. See &#147;Prospectus Summary &#150; Private Placement&#148; and &#147;Prospectus Summary &#150; Term Loan from
Avenue&#148; above and &#147;Selling Stockholders&#148; below. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock currently outstanding </I></B></P></TD>
<TD>27,784,384 (as of April&nbsp;24, 2024) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock to be outstanding assuming exercise of Warrants not exercised as of April&nbsp;24, 2024 </I></B></P></TD>
<TD>32,226,855 </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants </I></B></P></TD>
<TD>The PIPE Warrants had a purchase price of $3.71 per warrant. The exercise price of the PIPE Warrants is $0.01 per share of Common Stock. The PIPE Warrants are exercisable immediately and for an indefinite term until exercised in full.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds </I></B></P></TD>
<TD>We will not receive any of the proceeds from the Shares sold by the Selling Stockholders hereunder. See &#147;The Offering&#148; and &#147;Use of Proceeds&#148; for more details. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the proceeds from the exercise of the PIPE Warrants for cash for working capital and general corporate purposes. See the section of this prospectus titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Trading Market and Ticker Symbol for Common Stock </I></B></P></TD>
<TD>Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#147;DCTH.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk Factors </I></B></P></TD>
<TD>Investing in our securities involves a high degree of risk. For a discussion of factors to consider before deciding to invest in our Common Stock, you should carefully review and consider the &#147;Risk&nbsp;Factors&#148; section of this
prospectus, as well as the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement or amendment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus assumes the exercise of the PIPE Warrants with an exercise price of $0.01 per share of Common
Stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our Common Stock involves a high degree of risk. Before deciding whether to invest in our Common Stock, you should consider carefully the risks
and uncertainties discussed in this section and under the sections titled Risk Factors contained in our most recent Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;and&nbsp;in</FONT> our subsequent Quarterly Reports <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;for</FONT> the quarterly periods ended subsequent to our filing of such Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;as&nbsp;well</FONT> as any amendments or updates to
our risk factors reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus, together with other information in this prospectus, the documents incorporated by reference, any prospectus supplement and any
free writing prospectus that we may authorize. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our
business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected.
In that case, the trading price of our Common Stock could decline and you might lose all or part of your investment. Please also read carefully the section titled &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, and the documents incorporated by reference herein, contain, or will contain, &#147;forward-looking statements&#148; within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act&nbsp;of 1934, as amended (the &#147;Exchange Act&#148;). Forward-looking statements can be identified by words such as &#147;intends,&#148; &#147;believes,&#148;
&#147;anticipates,&#148; &#147;indicates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;suggests,&#148; &#147;may,&#148; &#147;would,&#148; &#147;should,&#148; &#147;potential,&#148; &#147;designed to,&#148; &#147;will,&#148;
&#147;ongoing,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;predict,&#148; &#147;could,&#148; and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts
nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Risks that
could cause actual results to vary from expected results expressed in our forward-looking statements include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding sufficiency of our cash resources, anticipated capital requirements, future revenue and
our need for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement of future clinical trials, if any, and the results and timing of those clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize CHEMOSAT, HEPZATO, and future products, if any, and to generate revenue
and successfully obtain reimbursement for the products and/or the associated procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our sales, marketing and distribution capabilities and strategies, including those relating to commercialization
and manufacturing of CHEMOSAT, HEPZATO, and future products, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of CHEMOSAT, HEPZATO, and future products, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation and success of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval and approval thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully source components of CHEMOSAT, HEPZATO, and future products, if any, and enter into
supplier contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to source melphalan for use in HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture CHEMOSAT and HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate
partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of potential market opportunities and our ability to successfully realize these opportunities;
and</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors discussed under the headings &#147;Business,&#148; &#147;Risk Factors&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments thereto reflected in subsequent filings with the
SEC, which sections are incorporated by reference. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date the statements are made. Except
as required under the federal securities laws and rules and regulations of the SEC, we undertake no obligation to update or revise forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting
forward-looking information. We caution you not to unduly rely on the forward-looking statements when evaluating the information presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of the Shares covered by this prospectus, except with respect to amounts received by us due to the
exercise of any PIPE Warrants for cash. We intend to use the proceeds from the exercise of any PIPE Warrants for cash for working capital and general corporate purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the Selling
Stockholders, upon exercise of the PIPE Warrants. For additional information regarding the issuances of those shares of Common Stock and PIPE Warrants, see &#147;Prospectus Summary&#151;Private Placement&#148; and &#147;Prospectus Supplement - Term
Loan from Avenue&#148; above. We are registering the Shares in order to permit the Selling Stockholders to offer such shares for resale from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the Common Stock by each of the Selling
Stockholders. When we refer to the Selling Stockholders in this prospectus, we are referring to those named below as the Selling Stockholders and, as applicable, any donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling the Securities received after the date of this prospectus from the Selling Stockholders as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related
transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second column lists the number of Common Stock beneficially owned by each selling stockholder, based on its ownership of the Common Stock
and the PIPE Warrants, as of April&nbsp;24, 2024, assuming exercise of the PIPE Warrants held by the Selling Stockholders on that date, without regard to any limitations on exercises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The third column lists the Common Stock being offered by this prospectus by the Selling Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus generally covers the resale of (A)&nbsp;the sum of (i)&nbsp;the number of Shares issued in the Private Placement and (ii)&nbsp;all PIPE
Warrant Shares issuable upon exercise of the PIPE Warrants issued in the Private Placement and (B)&nbsp;the shares of Common Stock underlying the Avenue Amendment Warrants.<B></B>&nbsp;The fourth column assumes the sale of all of the shares of
Common Stock offered by the Selling Stockholders pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration Rights Agreement, we are
required to use commercially reasonable efforts to keep this registration statement continuously effective under the Securities Act until the date that all the PIPE Securities covered by this registration statement (i)&nbsp;have been sold, hereunder
or pursuant to Rule 144, or (ii)&nbsp;may be sold without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 and without the requirement for us to be in
compliance with the current public information requirement under Rule&nbsp;144. In accordance with the terms of the Loan Agreement, we are required to use commercially reasonable efforts to keep this registration statement continuously effective
under the Securities Act until the date that all of the shares of Common Stock issuable upon the exercise of the Avenue Amendment Warrants have been sold thereunder or pursuant to Rule 144.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the PIPE Warrants, a selling stockholder may not exercise the PIPE Warrants to the extent such exercise would cause such selling
stockholder, together with its affiliates and attribution parties, to beneficially own a number of Common Stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding Common Stock following such exercise, excluding for purposes of
such determination Common Stock issuable upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of the PIPE Warrants which have not been exercised. The number of shares in the second column does not reflect this limitation. The Selling Stockholders may sell all, some or none of
their shares in this offering. See &#147;Plan of Distribution.&#148;<B></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name of Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shares<BR>Beneficially<BR>Owned<BR>Prior to<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares<BR>to be Sold<BR>Pursuant to<BR>the<BR>Prospectus<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned<BR>After<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Class&nbsp;After<BR>Offering*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilad Aharon <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,789,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Salamon <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,780,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,783,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Rosalind Advisors, Inc.
<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,776,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">619,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,845,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Bigger Capital Fund, LP
<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">653,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerard Michel <SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,205,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,164,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Hoffman <SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra L. Pennell <SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Johnny John, MD <SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony T.F. Lundy <SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">768,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vojislav Vukovic <SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Muir <SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with AIGH Capital Management, LLC <SUP
STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,813,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">738,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,075,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HLH Holdings LLC <SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodcourt Capital LLC <SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avenue Venture Opportunities Fund, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Percentage not listed if less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Beneficial ownership&#148; means that a person, directly or indirectly, has or shares voting or
investment power with respect to a security or has the right to acquire such power within 60 days. The number of shares beneficially owned is determined as of April&nbsp;24, 2024, and the percentage is based upon 27,784,384 shares of our Common
Stock outstanding as of April&nbsp;24, 2024. Unless indicated otherwise, the Selling Stockholder&#146;s address is the Company&#146;s address, which is 566 Queensbury Avenue, Queensbury, NY&nbsp;12804. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes sale of all shares of Common Stock covered by this prospectus and no further acquisitions of shares of
Common Stock by the Selling Stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 30,882 shares of Common Stock and 57,682 shares of Common Stock that may be acquired through the
exercise of options that are exercisable as of, or will become exercisable within 60 days of, the date above. Also includes shares eligible to vote owned by Rosalind (defined below), which are described in footnote&nbsp;5. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 82,197 shares of Common Stock and 57,682 shares of Common Stock that may be acquired through the
exercise of options that are exercisable as of, or will become exercisable within 60 days of, the date above. Also includes shares eligible to vote owned by Rosalind (defined below), which are described in footnote&nbsp;5. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based partially on the Company&#146;s records and in part on information provided on a Statement on Schedule
13D/A filed with the Commission on March&nbsp;25, 2024 by and on behalf of Rosalind Advisors, Inc., investor Company ITF Rosalind Master Fund L.P., Steven Salamon and Dr.&nbsp;Gilad Aharon (collectively, &#147;Rosalind&#148;), Rosalind beneficially
own an aggregate of 2,763,468 shares of Common Stock, 115,364 shares of Common Stock that may be acquired through the exercise of options that are exercisable as of, or will become exercisable within 60&nbsp;days of, April&nbsp;24, 2024, 1,418,909
shares of Common Stock issuable upon conversion of 11,986 shares of Preferred Stock, 224,262 shares of Common Stock issuable upon the conversion of certain convertible notes, and 2,332,256 shares of Common Stock issuable upon the exercise of
warrants. Rosalind&#146;s shares of Preferred Stock are subject to a 9.99% blocker and Rosalind&#146;s warrants to purchase </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shares of Common Stock are subject to a 4.99% blocker. The address for Rosalind Advisors, Inc. is 15 Wellesley Street West, Suite 326 Toronto, Ontario M4Y 0GY Canada. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 377,873 shares of Common Stock, (ii) 192,276 shares of Common Stock from a warrant expiring in
December 2024, and (iii) 83,334 shares of Common Stock from a warrant expiring in March of 2026. Michael Bigger disclaims beneficial ownership over these securities. Michael Bigger has the power to vote or dispose of the shares owned by District 2
Capital Fund LP. and Bigger Capital Fund, LP. Michael Bigger and Patricia Winter are the trustees of Matthias Bigger&#151;UTMA and the Andreas Bigger Irrevocable Trust Agreement. The Selling Stockholder&#146;s address is 11700 W Charleston Blvd <FONT
STYLE="white-space:nowrap">170-659,</FONT> Las Vegas, NV&nbsp;89135. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 302,668 shares of Common Stock held by Mr.&nbsp;Michel and 885,725 shares of Common Stock that may be
acquired through the exercise of options and 16,666 shares of Common Stock that may be acquired through the exercise of warrants that are exercisable as of, or will become exercisable within 60 days of, the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 74,330 shares of Common Stock held by Mr.&nbsp;Hoffman and 97,898 shares of Common Stock that may be
acquired through the exercise of options that are exercisable as of, or will become exercisable within 60 days of, the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 61,052 shares of Common Stock held by Ms.&nbsp;Pennell and 46,960 shares of Common Stock that may be
acquired through the exercise of options that are exercisable as of, or will become exercisable within 60 days of, the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 55,085 shares of Common Stock held by Mr.&nbsp;John and 209,946 shares of Common Stock that may be
acquired through the exercise of options that are exercisable through within 60 days of the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 889,286 shares of Common Stock held by Mr.&nbsp;Lundy and 13,153 shares of Common Stock that may be
acquired through the exercise of warrants that are exercisable within 60 days of the date above. The Selling Stockholder&#146;s address is 37 Rosedale Road, Toronto, Ontario M4W 2P5, Canada. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 126,882 shares of Common Stock held by Mr.&nbsp;Vukovic and 63,460 shares of Common Stock that may be
acquired through the exercise of options that are exercisable as of, or will become exercisable within 60 days of, the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 18,582 shares of Common Stock held by Mr.&nbsp;Muir and 158,696 shares of Common Stock that may be
acquired through the exercise of options that are exercisable as of, or will become exercisable within 60&nbsp;days of, the date above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Orin Hirschman is the managing member of AIGH Capital Management, LLC (&#147;AIGH CM&#148;), who is an
advisor with respect to the securities held by AIGH Investment Partners, L.P. (&#147;AIGH LP&#148;) and <FONT STYLE="white-space:nowrap">sub-advisor</FONT> with respect to the securities held by WVP Emerging Manager Onshore Fund, LLC&#151;AIGH
Series (&#147;WVP AIGH&#148;) and WVP Emerging Manager Onshore Fund, LLC &#150; Optimized Equity Series (&#147;WVP OE&#148;). Mr, Hirschman is also the managing Member of AIGH Investment Partners, LLC (&#147;AIGH LLC&#148;). Mr.&nbsp;Hirschman has
voting and investment control over the securities indirectly held by AIGH CM and directly held by AIGH LLC. By and on behalf of the aforementioned entities AIGH Investment Partners, LP, WVP Emerging Manager Onshore Fund, LLC &#150; AIGH Series, WVP
Emerging Manager Onshore Fund, LLC &#150; Optimized Equity Series and AIGH Investment Partners, LLC (collectively, &#147;AIGH Entities&#148;), Mr.&nbsp;Hirschman beneficially owns an aggregate of 2,736,125 shares of Common Stock, and 77,641 warrants
to purchase shares of Common Stock subject to a 9.99% blocker. The address for AIGH CM, AIGH LP, WVP AIGH, WVP OE, AIGH LLC and Mr.&nbsp;Hirschman is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Aaron Martin is the Managing Member of HLH Holdings LLC (&#147;HLH&#148;). Mr.&nbsp;Martin has voting
and investment control over the securities held by HLH. The address for HLH and Mr.&nbsp;Martin is 2305 Whitley Road, Baltimore MD 21209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Yitzchak Jacobovitz is the Managing Member of Woodcourt Capital LLC (&#147;Woodcourt&#148;).
Mr.&nbsp;Jacobovitz has voting and investment control over the securities held by Woodcourt. The address for Woodcourt and Mr.&nbsp;Jacobovitz is 2720 Woodcourt Road, Baltimore MD 21209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided by Avenue, Avenue beneficially owns an aggregate of (i) 161,827 shares of Common
Stock and (ii) 250,417 shares of Common Stock that may be issued to such Selling Stockholder upon the conversion of up to $3.0&nbsp;million principal amount of the Loan. Avenue&#146;s warrants to purchase
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shares of Common Stock are subject to a 4.99% blocker. The convertible portion of the Avenue Loan may not be converted and the Initial Avenue Warrant and the Avenue Amendment Warrants may not be
exercised by such Selling Stockholder to the extent that after giving effect to the issuance of shares of Common Stock after the conversion of the convertible portion of the Avenue Loan or the exercise of the Initial Avenue Warrant or the Avenue
Amendment Warrants, such Selling Stockholder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon conversion of the convertible portion of the Avenue Loan or the exercise of the Initial Avenue Warrant and the Avenue Amendment Warrants. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;8,
2020, we entered into a Board Appointment Agreement, dated as of April&nbsp;8, 2020, with Rosalind Opportunities Fund I L.P. and Rosalind Maser Fund L.P. (collectively, &#147;Rosalind&#148;), pursuant to which Steven Salamon and Gil Aharon, who are
principals of Rosalind, have been appointed as directors of the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain shares of Common Stock registered for resale
hereunder are also held by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gerard Michel, who is the Chief Executive Officer of the Company; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">David Hoffman, who is the General Counsel, Corporate Secretary&nbsp;&amp; Chief Compliance Officer of the Company; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sandra Pennell, who is the Principal Financial and Accounting Officer of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vojo Vukovic, who is the Chief Medical Officer of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kevin Muir, who is the General Manager of Interventional Oncology of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Johnny John, MD, who is the VP of Clinical Development and Medical Affairs of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the relationships described above, none of the Selling Stockholders has had a material relationship with us or any of our predecessors or
affiliates within the past three years, other than as a result of the ownership of our shares of Common Stock or other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder, or the Selling Stockholders, of the securities and any of their pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker dealer as principal and resale by the broker dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker dealers that agree with the Selling Stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than
under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers dealers to participate in sales. Broker-dealers
may receive commissions or discounts from the Selling Stockholders (or, if any broker dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but except as set forth in a supplements to this Prospectus,
in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of
the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions
they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders
may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by
this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to pay certain fees and expenses that we incur incident to the registration of the
Securities covered by this prospectus. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective continuously effective under the Securities Act until the date that all the Securities being offered by the
Selling Stockholders (i)&nbsp;have been sold pursuant to this registration statement or pursuant to Rule 144, or (ii)&nbsp;may be sold without volume
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">or&nbsp;manner-of-sale&nbsp;restrictions</FONT></FONT> pursuant to Rule 144 and without the requirement for us to be in compliance with the current public information requirement
under Rule 144. The Securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they
have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage
in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies of this
prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of Common Stock to be offered for resale by the Selling Stockholder under this prospectus will be passed upon for us by Cooley LLP,
Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2023 and 2022 and for each of the two years in the period ended December&nbsp;31, 2023
incorporated by reference in this prospectus have been so incorporated in reliance on the report of Marcum, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in
auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities Act and
does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the
exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to the
information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website
at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also access our SEC filings at our website www.delcath.com. Our website and the information contained on, or that can be
accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on our website or any such information in making your decision whether to purchase our
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc820991_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus the information contained in other documents we file with the SEC, which means that we can
disclose important information to you by referring you to those documents. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded, for purposes of this
prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We incorporate by reference the documents listed below which have been filed by us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000872912/000162828024013008/dcth-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;26, 2024, including those portions of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> incorporated by reference from
our <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000162828024016059/dcth-20240412.htm">definitive proxy statement</A> filed with the SEC on April&nbsp;12, 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312524115922/d711286d8k.htm">Form
 8-K</A>, filed with the SEC on April&nbsp;26, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Common Stock contained in our registration on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520128421/d915262d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-Al2B</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-16133)</FONT> filed with the SEC on April&nbsp;30, 2020, including any amendment or report filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any
report or documents that is not deemed filed under such provisions, (1)&nbsp;on or after the date of filing of the registration statement containing this prospectus and prior to the effectiveness of the registration statement and (2)&nbsp;on or
after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by
reference in this prospectus and to be a part of this prospectus from the date of filing of those documents and will be automatically updated and, to the extent described above, supersede information contained or incorporated by reference in this
prospectus and previously filed documents that are incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this prospectus shall be deemed to
incorporate information furnished but not filed with the SEC pursuant to Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Upon written or oral request, we will provide without charge to each person, including any
beneficial owner, to whom a copy of the prospectus is delivered a copy of any or all of the reports or documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically incorporated by reference
herein). You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: Delcath Systems, Inc., 566 Queensbury Avenue, Queensbury, NY 12804. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g820991g27q94.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>1,918,140 Shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock Offered by the Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May 9, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g820991g27q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g820991g27q94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4KB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C$M8S P,2 W.2XV
M-S5D,&8W+" R,#(S+S V+S$Q+3$Y.C(Q.C$V(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYD<W P,C,\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^
M1FEL92!.86UE.B @(" @(" @(" @(" @(&1S<# P,RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,C8M07!R+3(P,C0@,3 Z-30Z,S$F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,C8M07!R+3(P,C0@,#$Z,C0Z,S$F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,C@N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE
M87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R
M;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X
M03L@(" @(" @(" @1W)A9&EE;G0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA
M;64Z(" @(" @(" @(" @(" @9'-P,#(S+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R
M-BU!<'(M,C R-" Q,#HU-3HS-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" R-BU!<'(M,C R-" P,3HR-3HS-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @
M(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R."XP+C F
M(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(T+3 T+3(V5#$P.C4U.C,X*S U.C,P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M-"TP-"TR-E0Q,#HU-3HS."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871E1&%T93XR,#(T+3 T+3(V5#$P.C4U.C,X*S U.C,P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!
M9&]B92!);&QU<W1R871O<B R."XP("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIH96EG:'0^-3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!
M9T5#5T%*64%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!
M04%!0D%#5T%!04%!14$F(WA!.T%12EE!04%!05%!0B\K-$%$:T9K8C)*;$%'
M5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O
M2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS
M8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!
M.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!3D%%04%W15(F(WA!.T%!25)!44U2
M068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#
M=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%
M04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9
M155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R
M>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!
M.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%
M0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2
M-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#
M:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD
M65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N
M<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!-6MI5#-6>7%#<W1X3S1!
M3$AD;F,F(WA!.SEY9D5N=FY88D%)6C$O>6]F.#$O*W)(+T%.4%9N+S%7>D4O
M4#1F-3,R2#E3,&]86#5-9FUL66=3=F]5>'!U1$)*1$UW<#=1>4]C23$F(WA!
M.W5)+WA+:&1/.#DO;50U4G9F<39A:&9756M*4$]W=D]B24]X0F=N0D$K-G53
M;&=X6D)D02LU6'5F-5DO;C%P+VU3-&@P9EA9:S W5UHF(WA!.V9H9VU1:U<X
M-SEL2$EK>'5E>6MK2'-A,$=A<E9A07=(1DAE2UAR5V$U6%EQ-T9867$W1EA9
M<2MA+W=$;DM'5U4K8F1*:4QS66QS3U,F(WA!.W@Q4$5-,#!G66=D2VM+2R],
M3C,R5U!19F5G<R\O=T-C8DI:6"],=5)89&U73R]N5TU%:VA6-%)T4F$Y0E9I
M8WA/,&@K.2M#6'%U83DF(WA!.UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ.&XO
M35 X*V]F2TAM86)1:S!6<CDW9$DR;&Y.>4E"5U)!-$-R-E5T9&TV-7-.4&]0
M16IX6%@F(WA!.W=6-D(U43AY5R]M8GDS66$U8GA.0D9F4FPO4F-G;$=6:6I,
M561A37!O8W<X,DUW:UEN;W%C6E=R-%)V<GDW3W(S1C1:;DXR6C-L334F(WA!
M.THU."M:8FQ8>')N5U)I3T=K4'4W3U13-T9867$W1EA9<2M%9$8O-#=.:"]Z
M15)F.%1'9%I0-E-G4'4W3U13-T95;3@P*U503#-M:E0F(WA!.U=S3EIT1G5)
M>40V571!2EEM4#=C5#E64#1(=E5:8FEZ4WAM-&Q8>4@K64AK;E502F9M5V)3
M8FAZ3$=!2G)+-D$T*W)#>%!&<61I0T,F(WA!.T-015HP5VYZ:DQ'=V@Y2F9K
M:#4U;C@Q955&5RMF,4Y5,'1H8EAC:#9Y3%-S57 Y,EA9*TI"3V%46%E01&YT
M>4M8;V5987-1.#)F;78F(WA!.S5'.')Y=&(V;'%!92M4-U9L8D%Z5$0R64PX
M2T@R9&AM5&DP;51*=4)S<D,U4"MC;B]*9VU#>#9:<4QW-V-P0W-#=#$S;W9Q
M;78S-6LF(WA!.VIS=69E15=Y=GEN*V,O:TQZ3F-*85=T-#%P9E-N:D9A6'$K
M:3=K.4%R071'>%!90G$U:C5D1FMG3$ES95-78UII<2MA9BMC;U K57DF(WA!
M.S!V.$$W6GDO.&XU8S-N6F8P2#-O3%!V*V-A9B]!0UAS+W=$,C!:=BM455=9
M9F%8.34X179733$V<$PU;#@V959V3$U+>38U<4U6;GHF(WA!.T99-&U*859X
M-')%9UHR1S-51$QC5T=C+W!&<3@W=G8K8VUV23!,8V)7>3%#-DE0,B]4:6I1
M:F9C1G!/6"]#-6U2-TUY2&U1:3!4<%@F(WA!.R]/4U U9EAK:5(S85AM;D9V
M=%-4>$LX65!Z:&%2=CA!:&-%*WIC9S5553(Y2S!R5CE,,6%Y4SDP>39I=DQ3
M5#=%,$QH,7(Q<%5D0T\F(WA!.S1/-'I";D%X3D555E,S>E U-3AQ958T:$IR
M96]X5W)-2WAW8G9--#A6:5%--4AV4VU4>%E*-5!P0W903'HO;DHS>51%+T<R
M,"]53&<F(WA!.T%M<FQ)63$K:7-H4#-G6FUX-TUY9%-%5VIT22\U>4\O3'4K
M:U-/-4XS<').448W;45.1T-F.'%&<%13=F-Q36A0<S-)3U9&3#!N5&0F(WA!
M.U4P,U9,3DPS5')Q2S=T2D)62C181&]F<%=U+W1M1DM*:6%)<%5(-6LX,#9$
M-5HP-&%J<FPR3$]Z36EX3$E69'E8645H47-A=7A.1DHF(WA!.S)'4W@T<%1.
M4D9L6'EB*V-(;4A2+TU0;C(O,5A2-VHV,5E42D%)<'5$>#%+47%J9D1)<4YS
M=SA--DA2-#51>&=3-6],,3<X<F9Z9"\F(WA!.TQZ42])5VLV5G%M<F96-RLQ
M4U%4=R]6-VPK2F%:,TAX2D5Y;C172%$U<F16;SAK.&A)1S-W5C9T-60X>F%(
M-6LP,&%L;W0R=#5:1C(F(WA!.VHY5E9D0TA8<7)+-%9G9"LT>D%Y67!13E-&
M1DPT979F.3=*+RM-:B]!4$5J;E5X-4EF8B]!2FHX,658=DQD;#EC,74K:G-O
M0U-%-6LF(WA!.VPS239H155&,T\O-TEZ;'-E2U5Z55)A6&UT.2]Z:S,U26AK
M-%=T:F8S44(S:S124G%F.$%6-5-C=G9!>D]J,EIK4$UH1G S-6$O4&XF(WA!
M.SAV=&5V17,Q=4IT3G5*4T9I5R]266QD:6%!0U)':U%(+U=96E9L,$=3079N
M-VMS.#%(54Q05')#-'8W,E%1,FQR1S P.'!Q47%)3U0F(WA!.T=G,T]W>D5J
M17E.1&UR0C1F>F-T:'%B,C$W<&HR;'9&4G)G=$UJ6$YV17A10U=E,T$K1E(V
M<6PK1'5Y5BM)9&-Y:G!$5F<S*T\Y6'DF(WA!.VIO=B]!0C)B1"]M26DO-&U-
M-D-F,&Q!9F0R8VUL,DMU>%8T:B]W0352-E1%*VAA3G$T045S1C Y;U=P.%)7
M94UY044K04U"*R].<#(F(WA!.UA0,4=0:V=S6B\U>&5V6E4X,F%T66=N,' W
M1#$S6'-7:&U25E S5$A,*S%)*V=(>E5-,B]0<C@P<G9Y-6%X*U@Y1VPY3%9R
M-DUV8S,F(WA!.TMN-&])0U-O-&5$=5%A2'-.*W1$;4QO3DM*;FEL>4-8:U@U
M6"]L4'%V;G4U;75P6GI:-E)B=GAU8C1R>F0U0T]2:FI"24)B8T9I5'0F(WA!
M.UAV,'I:87)6:D5+-6Q$,G10*V-C=GDR5S)-2FIV2&MP+W91,7=F52MD06]4
M+VAC,68X;S5B-DIE3"]M,2M5.7@U1W4T3&DR;F$W,%<F(WA!.SA9<F)Z=4%*
M235&1F94:W!24V%B<5)3=2LR,F)04V%S6E)2*V])97<O=T1/4"\U:%A8;5!1
M<#E(,5-9>F%P<$E8:$TU<3AT<S)Y;&HF(WA!.S-:0T]*4&A4=FUT-U$P-&A,
M:4A)<%E"+WIL0B]Y;5=L+W=$8D]8+VLO3&U:,E@Y0CDV0WHW+VY';B]Y6',O
M.$$R,%IV*U155UEF85@F(WA!.SDU.$5S9R].=CAX13AL95<O<D5!5U16-S1T
M1' P5&)Q1T%Q.')$=7-923(W:V=:5'!.4#1S<39$;7(U9C!N4V9.;FXW>D]9
M66UK,40F(WA!.U9B<VU3-'5:;5!&14A6-4<V26DY0E0U061";2MN3T='2&-%
M4&)D12\U>&<X=E)7-FY7.59U<G$U24A*8EAH1$5$,TAX<DMZ9E!B-5HF(WA!
M.W$U.7%3+VA!5VM(-6DO-7AJ,#$T<%@X=&%V26QY9W%,5RLT>4M4-$=324E5
M+W=#04]3>#EQ2"M)9DID:S,O27(X<U!.9FQ/.3%++S$F(WA!.WAX8DQC4FDS
M:# K3U):1F,X9R]R3G=*549A8U8W-VYP,W(Q,G%H:T%%57-5.#1F:THU-#%J
M>C5F,U5.>$9,<&PO3S T,4LT;$A+3D@F(WA!.U!,,#)J1EA*5#=+,$9+539D
M<VI$<CAC8UE(561%57E84R\X06Y'6'EB1D5%,4A63'DX=2\R:D,P54-F46A7
M5G8K1WI(;#)P36Y90E4F(WA!.V@X-&8X-'EZ5S%P2F1E5CE193=E349H65A9
M55-/04]I4V]&570T07%0;FPK2'1/>E5X4S X>CAK965V35AK6%AF5G1Z27-+
M>6-.4S F(WA!.W57<7))1DY'5FQ)*T)X,F%L469A;WI/>C1)-5DW+T%Q*VTO
M3DAL>E%V>E(X;#)):G9*26)+-&5/+W1,:4U+5T1"1U1I-FYW16I+=W(F(WA!
M.W-C,%=,2DQ"33=B.&MV;'HX=W9+,%!L6'IH<4=G43-$6%56;C901V0Q0W,S
M<7=*2V%G5C9E<%1..7 X=FE1174Y1#!0>4PO>FHW8F4F(WA!.UHO2VUN-C8K
M='9A=&5Q-T<S1G5(0SA*1VHK,39I,2MX6'!M1FXW44U*;4YC;' W9"M89FM3
M>3AK*UAZ<$9R8U!D97!-.7I.4$EO570F(WA!.TDV<6UY:71">&I(8S5Q.5)N
M3U=8155V:DLW<#ED;35D4%9A=$]T3U)Z<&\X:U!2=$HX<V5E+WIG.'<S3W-8
M37=G<VMB:$IE4VAV46@F(WA!.UAQ24E%2#)I;TYA1#5S86YF0VYL>#9A4$-/
M879152\U>&(X=FDS0W9R9#(Q>%1E45)X:$]8:G=.5%0R-5IH+WEP3'5#,#A7
M+TU$>4XF(WA!.W%0:W9Z0RMK6&MI>F]55V$Q=6M(15-X35-!,T5K.%-#<$)&
M96\X33)M;GIJ3$AI0W9F=GEK,4,T.#=F;$ID85!F6$I&,4%*=$TK<VXF(WA!
M.S1N0SA&848R0BLQ>$1G92](3E!Q-&I&;45H-S!T2'E$-71V=%<Q0U,T=$ER
M2S0Q:$HW6%=.4T4T;70R=&)H65DU0F%W:V5O<VA703 F(WA!.S5"86-T>3-%
M669Z14%"4G5U43@O3EAZ5F]V.$%X,F)$+VU):2]W0TIJ3C-0-E-G4'4W3U13
M-T9867$X5"]W0V-O=%5J5'DY;S)L5D@F(WA!.W%81C(Q,50Y;TQ"15DO=5!R
M-71/>30K;VYY45=,9CA!3TPQ;DLO;3=68C!!*VQ$<#5H63EU53 P8DPK14IZ
M23=54&]!.#%$0W9Z9C$F(WA!.T=A+R]!1$HQ*U=5:VU+-4YS9U!:8F-#24%F
M.$%!6FLV3TY9;RLU4VY8;$0X.79-2&Q8>2]B84IP*VU71%<Y='I0<7E,3#9J
M<S=&,EHF(WA!.WES:6=N96Y4<&Q78E%2>5,T:5-T<#$O,$Y"-7DO=T-R6' S
M+T%!32\O5EA++W=#4S1D-5<R4&5E9GIR,2]W030V161(,4A4-T]'2#$F(WA!
M.U5M5U=%4V@Q9$LP<'ED:'5'239:9&<P56-C=4E%<F%C+W=$3TTX5CDO:G$U
M;6EJ8S)N,4=73S5L0VMO0UI),E5&=6=*2S=:5C)M4C0F(WA!.V9N86A%9CA!
M3U5(+T%#;5=L+SA!8D]8+T%*4'DT3WDO;U!V57,K+S5X<"\X;#=0+T%.=$=B
M+VLQ1FU(,FPO969"3'I4+VY*4%5P<FXF(WA!.SAW23=2=&]R1WII4D8W5FM,
M4TTS,#AG4&]Z3S=.:E=/*SAO3#!B+VY'<E%R5S X;'HV<T5"=3E3=5A6-64O
M<%%F06EF.$9Y4# U:&0F(WA!.W!:0UHQ,$%313<O32]W07A8,7)08C9287E.
M0VMS6')81&]31UI3>%96<4]G*T4Q.&-O=UEW45I&-3=T<E=49U)J:6%S5U=#
M5W1X8U<F(WA!.SAQ>E%33D9+=39Y25-R02]-67ID3FEM66UW84Q09$@O041.
M2W=,2'%L=3!K<6EN<G<X45<O=T):1'A!4'E0,%IJ>49/+W="4#)T=%4F(WA!
M.WAV,VA1,7)Z,V5A9VAG<VQ.<&)N6C)R*SA99492.6MF3$U03FM.54=C.6-:
M-U(R0U)23WES2%5K341534119R]03EA-<D(V5C52,4LF(WA!.S1V.$%303EW
M96-S3&U)=65R04%-0V9F-',R=6MY1V-.,UHT6D=59#-Z="]Z:VAO5G!P+VYM
M2RMT;$-F<%,Q5V4T54-G.5I'36).="\F(WA!.TUQ<E@S<6,V9G,S251J;SE#
M,D8V4"]Z:E!Q8W1Z-49U<D]1;&A9,S!I=S$V0T]216LT:B]!1UI9+U1M1C)N
M1W-G4&5&1'@O."M0.$$F(WA!.WEA*W5F.4=V+U5(1&UY,$@Y>D@T+V563#9%
M+TI(+WE6=6<O.%DU=BMO:51.3G)F-S)35V-::7$K0S=W13-S-$<U36I52"MY
M3V1B2&LF(WA!.V@Y=6554$QT<C5C.'1A9F\Q<VEQ='!#<7E-=C=C<$9:2%!U
M>FMN3U=Z6D1/4FME<54T>718>G0O>FQ+:6I73D)C1#0R=#4Q2CEG-FLF(WA!
M.V9R3V)R<W8V6DE,268K8UAF*U57,6HO;4](+TIL8V\W52MS9351.6]Z5TIF
M0T]I+SAD;7<O=T-9:4PO:5EZ<DHO4U5".3-:>6%867$F(WA!.VQV;4AZ2F]N
M;#-46DY3,6DW4S!T62\R;E!X33-:555F13=(=T%Y95!(2UIQ258X9R]M5#4U
M=79/;FUE8E9(57A7:4%15T9U97%12U,F(WA!.U9R5#EP:5-Z935P,$=D2G!S
M07A1<$0V22]);GE03C59.&]E=F5X;5!5.5A:8FTT:EE56DEW2U%X;C-#:W-F
M07143DQR."](4&)K178F(WA!.T,O>GDP1V)34'I(,4YM56E$55-T.6)V4V=9
M4VHT+W5L1$1.=&]C;D9I2&QS9W9C4'E#.#175W1E4TQB4VI)0G%E:DPY6&YH
M2BM)=S$F(WA!.U!O>4M0-650=R]-9DQ.5G(X2FIK=G!*3#!Z349867$W1EAZ
M5"]W03519CA!2UIA6"]W0G,U9CA!:R],;3@W3"MG*SE"6C<O>FI1>6XF(WA!
M.SAV8F=!,4LV:DU'.6HV54HO:FU(,FXO969"3$%V*V-M=$%M='9.9&IR4V]F
M<3)O5W=I9"MO.6%":4-08CDR>69J;5HR6FMU0FHS1D(F(WA!.UI$+WIJ4C5Z
M<WIP.3$U575:0DAD<$LQ,5E":E0Q16-$,458,U%R>2M2.7-P-U1W;7A-8VQ$
M,"]Z<#5/6%@T;W!O2D)$9C(T2WAS.64F(WA!.T1)5%AI,4%32TAO8S$K3$QW
M-V1(5SEO.6YJ54%%1W!":4YP*U=F;4(U;%-D;UE9<2]&2GDU;6YS;T<K1U=1
M3W-X.6HU8C-O0FYE:F4F(WA!.UA.03 V3G)A,VEJ;&YJ03EE4U1I.'171E)Y
M+VQR,D=5;3-E-$Y*:GAI9U!I:&1A.'!A4G%F<4<P.4\S=F\V8VI(4VQ4=E-2
M1CAF2'(F(WA!.VQ/6$1X0D=84U)L=4YI:T50:U!7+U8T3S!3<%AE5&M32V5W
M<%A-039/6DQ42%131$YT2C!Y1%1,1DQA23%#,5HU1'-763E73V)$1FDF(WA!
M.T5),$A/:$%21E!L2#@X4$]6<#5N.#=Y>5=,:5A4.4]I1FYB>6IP2559=$DT
M.6DW14$Y=T)N5&%(0V-E4&9M56PV:B]Z:39Y+S19,6@F(WA!.V%J:TPQ4U8W
M9T=*84@X37=E,5!R2'554$PO>C=J9%!Z5C%L;49"271Q>4AX2#%32F8Q<6-Z
M=$%F,TDK4#-Q6'90-40S,71D9FQF<$LF(WA!.U%U1V4Q33A&=W9D2D)--SA4
M+W-85G9K8S%/=FE2;$M8;T=9879H2"]!2UA(+U)X+WAV;E=F=V]F9#)C;6PR
M2W9N9CA!-7EM+S0V=FPF(WA!.R]W1#1W6$@O04).33-06F9+4T-Y1"]N1C,O
M;$9T62\U:F@O>5I82V4Q4')(=55084TQ:5AW5$).3&)836-Y8E-W=4A7;S9-
M:'%+:C4F(WA!.VI/=4ES265J+W=$47<O-6TO=T1,6&(O.4DX95E0.&Y9=35B
M43$S*V9N-6]80TUG,59)1EE54&\R.$%0,$U566HV36M.0FE(4F)34S(F(WA!
M.S!F.$%-4'IZ9D-:24PO5W!Z4E)C>6PS:E%%-T%Y>452;U!P07DP>GA9:#!I
M<C(S.'-0.$%N2"LR,%<T:#%J>D]Y6&UP4D535S%J2#@F(WA!.U5%3$$Q1$]X
M<#9J:B]G4B]L9'18<74P1$PP=S)#865Z6G)&65@K85 U8E=0;FI25G1Y-C(R
M<5=H3#9F945%:%,Q3U-/0BMW.4)8=S8F(WA!.RMX>71,<51I;&94<7(U93%$
M4U!02#5F-C9K:WE81VLV:$-4-D8S1U1W:TAF:$E09V133V\K9VI.-T=E4$Y(
M=D-'8C)0+T]42&YU0S,F(WA!.U=+-71B0SAK6')/.&-I3S,K<TDU1E0W;$=9
M<W5Z35I/>$E7,&PX>2]N9"M9;FU:1%EP8TQ9,C@O=T<Q,#5':EHV-V-3-4QY
M;71A14(F(WA!.W%(=WDS1F]C8TXK9G97,W-N+T]0,FDK9&1+.'98<V9M2DI)
M3$]A4DI.371B9VXQ:W%'.5EL5#A32S-W554Y-FUM*RMT-U%N:FQ)8U F(WA!
M.U!Q;$IF*V-K9DDK<#9N0EDK63E/:&4U*V]X=&(S.%59-4US4F)M:V=58FM+
M>&)L.#8Y2S5:,F)N15-9;G%P94\K4U!Z33@Q*U1436TF(WA!.VIZ26)7-%E0
M4&%4<#9K5$UU,TQQ<DMA8DAI4FUZ>C9A1U@V:U!Q,WI:-54P,WIR-59/;39K
M:&DK<TEK,$UQ:7)W5&-A<38Q<#!R46HF(WA!.W5+:D]E>%I4:6Y94RM69DYV
M:T1Z;#5',4Y:3'%+5T]/2U%.6C9V8D9V4TI"<7),274V4'0P3D1N45ED4D1+
M3G9K:&LR:2\X04]2,S4F(WA!.V=A9F)#,W5H86%M1D%#>EA-8D-8655&5VEA
M34XX>4LK*U54-T]X:S),0S)P-C<O>FM2*UE7<5%',W1N=#E+4GAX6C=/32MQ
M82M$>70F(WA!.TE6*V$P3TA(,F1J:G5D,710+WE'.&UE9FPX>F8T;&Y%,6IP
M:S!->3-%,3%Y-3-2;%$X0T5B-&Y!:TMV>4]X<#%Y;E@U<V9$=VIC+V,F(WA!
M.W)#.64P<CAZ=GDO.'E487!C4S-.=&53>4UX,65%;#1,9W-E4C5-455B:V1Y
M:FHV37ES8SA784Y$;#-+>4MY+S5Y6C@Y45<V>#-&;EDF(WA!.UA5:3E:,VIK
M4FTK65-25BLT1$M*9&U9>GE*5S)0*V(O04TV9E!F;6DS:W-P-VA,3%0U:'AK
M<S=*5$=R:G!2,UEV27=08V-Q2'=Y-T0F(WA!.V]S94TS>E!M=&]+,R]+9GHU
M3C5B;CAW:E,U57-O2TXV5&=R3SA:*S%):TI(36]V56YW,T9A1VMZ<3A9;'<S
M=71)6'E6*UEF;69Y8F,F(WA!.U1Y84Y/:7@S4$@V>F)424I),S16-&MJ66=I
M<#-5:D1N,#A-;SE3=EIV>F$O3&Y5+T\R9S92-7@P94%.<D1734Q8=&=M,W%2
M=6YQ:C F(WA!.S8Y6%%U4E$W<U!L438S4V%K67!'179P=$IE3"M84$]0;DQY
M5F9Z<G!L>DQP.#=(:F0R:W%!<5-V85-+54=J1'AP55IS.&U'1U5B-V\F(WA!
M.V92,S5)9FU&<C-N3%-.46PQ;%EF6'-::VI35T9#;DY84W9X0W!&45(R>E,V
M-U1X>%-(1#%3*U=Y:G)R6E%Q431U84933G=F57!3;6(F(WA!.S<K2#1)9F1U
M8VUL,DMV;FXO;DM:5R]36&PY<4AI66)G0G4Q43962#0U=65Y=55K1E O.$%N
M1C57+W=!2S9U84=H=FA1.71O57EN=%0F(WA!.S9X-VQ$,F9.66QJ,7HO>7(W
M-GA,.6$O4E Q;FMF5SE8-G1Z-3$K3&QY,W)8<EA,:#1L8F-8,G%P+W=$24YF
M.$%T5&8Y3W5(.3<O4RLF(WA!.S%65S$O=T%!97-0<6XV2SEB.6XP=G$S3#9/
M3RM!*THQ-'9T5FM'57$W1EA9<3=&54QQ;C9,*V]Y+W!8,%!Q1E S+S%R:#9.
M4#AV,5 F(WA!.V@K+TI2=3EU879.3E(O-D9Y*W-J-G@K:&95-68X92](:%AB
M<C9(=U4K93):,&9Z3F)C4W-T.&\O.'$P-68X-G K:697-&UV,40P4%<F(WA!
M.W S-6-0,VXO04%762MB>&8T*TPT<7EJ361867%X:30O-59J*VMF.$%39C!,
M*VMU67(V;C%4,2]5<G0Q*U!L6$QX-'1B8U9F1E=4-5$F(WA!.W%Y9C!F4FLY
M9FHV2$4K<GIP=S15*TQL6&%L3W5%2S@Q,3,O;UAZ,5<O4T@V1#EA9S4O5B]4
M-61E+W="6#-R*T]:=5 X>C T=G@W,50F(WA!.U1Y="]Y<&XQ-"\X040S-D8K
M=6-H-EAP96@Y6C5B530X=C-V.751>2M0+T9X57)/8WA&57)R-G(Y6&LK=#A0
M<3-%*W(V=$](2'9Y-6(F(WA!.U4K945897EV3DYB+T%/:&5F5E Q-SE#97)8
M-'9Q,W Q<G8Q*W)D+TA--D@U;G!X9FHS<6YN;% O04I61#E95"]!07HK:'9R
M=DPY,SDF(WA!.U@Y1#9Z5VYA=C<S2W-V:E8V*TML6G!M2W)%=%8O=T-65&9P
M02]P8CE!+W!$;G8X05<O<69R97!8+VEZ-'568WE)94Y8<#1Q*TMS<FHF(WA!
M.SE0,#$Y3VYP,$A$:E1J>'!T4VYB36-Q:R]M1"]!05IY:B]X1BMJ=590,U@V
M43E#=$LO<RMT+T1,8V9(+T%!,SA&4D]G+W=#2&9Q2B\F(WA!.U%(,5 V:GI.
M9G%(<&5L-FQ">2]U=F@U57!8235/2R]69"MA;UDO-$PO4VTO-DXO4VYQ+SA5
M9E=05S5F.$AZ-6946$IE=75T2VY75DLF(WA!.S=&54)R2#9".490,'HY5CE$
M;"LW*W5E;G<U,"]:.51A=$UN1&DO:'165%,O,%8Y5%@Y1F5H.51Q94@Q6&@V
M5F$O1E0P+V@V.6-%<G8F(WA!.V9M<4QY2W8O,E$]/3PO>&UP1TEM9SII;6%G
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#ID,S,P9C=C8BTX9CDV+34U-#$M86-B
M9BTU.#,T8F9D938Y93<\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z9#,S,&8W8V(M.&8Y-BTU-30Q+6%C
M8F8M-3@S-&)F9&4V.64W/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-
M.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YU=6ED.F,R-6(X8V)A+31C-#8M-#4R,2UA8S0R+6(V8S(Q
M,C4T,34S.3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#IC.3$S,S%C9BUC,61B+38T-#4M868W-"UB
M9#,W.69A-#,U930\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q
M.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12
M968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HX8V$X83(Y8BTR.3<T+68P-#DM.3AC,RUE8S<P
M-3%C.61E,S8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C0M,#0M,C94,3 Z-3 Z,3 K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R(#(X+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#ID,S,P9C=C8BTX9CDV+34U-#$M86-B9BTU.#,T8F9D938Y93<\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C0M,#0M,C94,3 Z-34Z,S@K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R(#(X+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A
M=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E
M871O<E-U8E1O;VP^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z
M3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X
M4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \
M<W1$:6TZ:#XQ,# X+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#
M>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP
M1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO
M<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3 @33TP(%D],"!+/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z
M0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3<N
M,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $8!; ,!$0 "$0$#$0'_
MQ  =   # 0$! 0$! 0          "0H+" <&!0$$_\0 4!    8! @0# P<%
M"@L)     0(#! 4&!P ("1$2$PH4(14B,18W.79WMK<:.$%XEQ<C)#)35E=8
ML]<9)C-"0U%UDY32U31$4H&6LL'"UO_$ !T!  $$ P$!               "
M P<( 00&"07_Q !3$0 " 0," P,&!@T("0,%   ! @, ! 4&$1(A,0<3010B
M46&!\#)QD:&QT14C-39"4F)S='6SP>$(%A<SE+*TM3=455:"DM/5\225U$-R
M=H/"_]H # ,!  (1 Q$ /P!+%YR%=\EVZP7R^VF=MEPM4J]FI^P3DD[D).2D
M7[A1RY7<.7*JB@@950W;3 P)(I]*2)")$*0/1:SLK2PMH;.SMX;:UMXUBA@A
MC5(XT0!5 50!T',]6.Y)))-,;GF=SSZU\IYAQ_+K?[T__-K9V'H'R"C<^D_*
M:/,./Y=;_>G_ .;1L/0/D%&Y])^4U^G&6*P0BY74-.S,0Y(8#$<1DH]8+E,'
MP,59JNDH4P?H$# (?HTW)##*I66&*53R*R1HZD>@A@11N?2?EKK#%?$.WRX5
M<ME\<;K,X0R#0Q#H0LE?9JV58#$$!**E0N#B?JR_H %,"\.H!R>X<#$]W7.Y
M#1>D\JK"^T]B968$&6.SBMKC8^BYM5AN!ZMI1L>8V- )'0FG@;4/$OYBJKZ,
MKN\#&4)E.L&.B@\R)C!HTIN1&*0B4%I!_5%G"=&M*H<AZ&,4./B% PG\RL8A
M4CQ1J+L)QEPDD^FK^7'S[$K97[-=63G8[(EP%-W;@\MWD\L/Y(!W"P_IY^O^
M%5B;:]T^!MW6.FF4-O\ D.&OM85.FVDDV9E&D]6)4Z0+'@[;7'Q$)BN3"1.9
MP:2;1 ';?H?QRKV.7;O%J[9S3^7TW>MC\S92V=P-V0L T,\8.PEMIT+13Q'I
MQ1L>%MT<*X90L$'F*Z#U\:LT:**-%%&BBC111HHHT44:**-%%9VO'7R%=K3Q
M,-PE?G[1-R<!0U<>UVF0;J1=*1%9AU<5TB8=,H6/,J+6/3?3,I)R[X6Z1#.Y
M&0=.ES'45$0NIV1V5I;Z$PTT-O%'->"]FNIE11+/(,C=Q*TK@<3E(HXXTXB0
MJ(JCD*:8GB/,_+ZA33_"]9"NSZR;JL</[/-/Z-&5K&]IB:P^D'3N(AI]S+VB
M-?R4.R<*J(1CB49 W1E3,B(>T@81HO.\:/:BE'W;[96B0:>ODMXDNY)[ZWEN
M$15EEA6.WD2.5P TBQN6,8<G@XY.';C;?*;\^9_\[U7WJME.4:**-%%&BBC1
M11HHHT44:**-%%&BBC111HHHT44:**-%%+6S=Q>^'?MXR/8L293W$,(O(%1=
MFCK1!0-#R?=R0,FF4HKQ4C,4JES\$E+,S&%&1BRR9W\8Y(HTD6[5TF=$O<XK
MLVUKFK&#(X_"/)97*\=O-->8^T[Z,])$BNKJ&8QL.:2=V$D4AD9E(-8+ =37
M76WO<CA#=5CEIEG;_D&)R10G<B]AO;48VE8Y9C,QQ&ZKZ&F86>814]!2S9!X
MR=*1LS&,7@LGS%\1$[-ZU76YS-8/*Z>OFQV9LI+&\5$E[J1HY \3E@DL4L+R
M0S1LR.HDBD=>-'0GB1@ $'F*]OU\FLT:**RH]R>1[SD[/F8+M?+1-V>S3>1[
MFX?2DO)/'SCI^44B5NS;F<+*>5CF" $:1L>W[;./9(H,V:*+9%-,OH5@K&TL
M,/C;6SMXK>"*QM52.*-$']0F[MP@<4CG=I';=G<LS$L2:8+'<\R-SOUJX'P[
M%\N-YX>94[A9)BR_(S-V0*;65)I^YD5XBKM8.DSC.#:N':BJQ(YE)3\JJR:]
M8I-$W7EVY4VZ:29*H]M=G:VFM-[6"*#RK$V=U.(D6-9+AIKN%I650 7=(8P[
M;;L5XF)))IQ#N/B.U/;U$=+HT44:**-%%&BBC111HHK(OUZ05KU=_P"'LQQC
MRT<.^+E+-0J78I,<RY.;C(SM6@Y=^*"*D'V4!>2#%PX%%+J-VTQ4Z"=1NDH<
MQYU$[9KZ^M]:S1P7EU!&,;CR(X;B:- 2DFY"HZKN?$[;GQIY/@CV_33Q?W%L
M.?T38S_]!U;_ *5J*?LKE/\ :5__ &RX_P"I2J^;L6V3;;;VJC&V;?,(6=DJ
M02*L[#BBAS350A@Y&(="2@'*1BB'H(&(("'IIZ'/9RV8/;YG*P..8:'(WD3
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MW#9<J;EJLBX125)LV=Y=8^ZM[VRGDMKNUE2:WGB;ADBEC/$K*?41S!!5@2K
MJ2"$;\C6:7Q)-FLEL5W:9"P<*KU_3!%K=,4SC\.;F;QG9U72L HZ6 B97,C!
MNFDI49IV1)!%W.5V2=-T$FRR) O3H?4\>K=.666V1+KSK7(Q)\&*_MPHF"C<
ME4E5H[F)225BGC5B6!-,,-CM\E,Q\.;NSD<1[MI+;=.2:A<?[DX1XC&,G"P@
MSC,JTF+?3U>DD.X84FIIZN-;'6G9$2IJRTDM5DE5#^SFJ>N$[;=.)DM.1YR&
M,>68*53(ZCSI,==R)#,AVV+"&=H)U)W$2"X( [QC2D//;T_35V&JD4[7\$0
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ML9?>6SZC[M_^YVF_TV__ &%O2H_'V?OJRP1 H"8P@4I0$3&$0    YB(B/H
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M^)OU9CO[DE/)\$>WZ33WM1)2J-%%&BBE9\3#BCX=X?F.9)J:1A[KN*L42O\
MN;8A;/"KNTG+I(Z;*WWY-HJ#BOTF/6$''\(.TDK2J@I$UX!$LE*0\@:$T!D]
M97T;".6UPD$J^7Y)E*J54[O;698<,UVX\WS0R6X82S_@1RI9@OQ[<O?T?QK.
MNR+D*XY9OEPR;D&=>6:\7VQRUKM4\_,47,I-S;Q5\_=&*0I$4$S+K&*W:-TT
MFK-N5)HT11;(I)$NM8V5KCK.VL+*%8+2S@CM[>%-^&.*)0B+N=RQV&[,Q+.Q
M+,2Q)+).Y)]-62>',V%RN*\=V;>CDR$5C;7F:$3JN'8Z0;BB^CL3E>MY*7MQ
MD5B@HB&0IF/C/8AS)I*'K5?0E6JKB,M21M5D[;=7QY"]@TM82A[?%RFXR;H=
MU?)<+1QVVXY'R*)Y.]&Y'?S&-@LEN:=0;<_3[^_OM03N9PZTW";>,VX.>*HM
MB96Q==J*V>K@(I1DG8:^^CX>7$"E.(FB)99E)D]P_P"^-"\R'#F48:P.3;"Y
MK%9906..R%I=LB]9(X)D>6+J/ZV,/&>8Y-U'6E$;@BLKVTUB?I-GL=-M46ZA
M+/4IV7K-CA7R?:>Q$]!/W$7+QCQ(>?;=,)!JX:KDYCTJI'#F/+7H);SPW4$%
MU;R++;W,,<\$J'=)(9D62*13XJZ,K*?013!Y$CT5<?X=[>G6\P[7$MJ]BF&Z
M&6=NIY(L-%NW!"OK/B*<F7$I"34>10Q3NPJ,O+.ZA+(-DCDB8U.H*N%!/,D
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M3R ',GD*Z6LZ#C0[U(/>GO/L,[0),DMB+$<*WQ-C:5;GZF-E:PTC(R-FNC0
MYD.TL=FDI D.\*/-_5XRNNE"(JG.BG=GLNTM-I;2\$-Y&8\EDI6R-]&P\^!I
M41(+5ORH+>-#*OX%Q).HW !++'<\OBKF_AK&*7B"[+1,8"@.YG#10$P@ =1K
MU"E*7F/Z3&$"E#XB80 .8B :^WKK[S-4_J+)_-:2D_-0OPA[^%:>NJ%4]66%
MO+AWU>W>[J(*22,@_B-QN;8]VD<HE$JS7)5E1.( /Q(<2=:9@YE.F8IRB)3
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M$.*@#[HBG*J(\P'DJ)>0C&4O8QKN-RB6-C.H.W>Q9*U"$>D"=H9-CUYQ@^D
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MBL2M%G>76/NH+VQN)K2[MI!+!<0.T<L3C<<2.I!&X)5AT9258%207*F2W/\
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+BNI-<_6:-%%?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g820991g27y90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g820991g27y90.jpg
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M$0$#$0'_Q  <   " P$  P             )"@ '" 8" PO_Q  M$  !! ,
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MI38=GO4;MB[1,>ZDDNNU*O1,W#U8&68;RI0Y=OG9]<C%#YQDG(E5>?<:;'/
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M?U_XT0OJ30?F;TWJ;E;96A^I MLWGGK59L'OBFDRH44!LR?7-2<H;<IK.PR
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B62>RRF"S%UB:K H8F>&-22S =5)(^20!\Z::7]9^TU__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
